01 2Gowling WLG (Canada) LLP
02 2Gowlings
01 22213833
02 22286330
01 2RANIBIZUMAB
02 2Ranibizumab
01 2SOLUTION
02 2solution for injection
01 22016-03-28
02 22018-04-03
Patent Expiration Date : 2018-04-03
Date Granted : 2008-06-10
Brand Name : LUCENTIS
Patent Number : 2286330
Filing Date : 1998-04-03
Strength per Unit : 10 mg / ml
Dosage Form : solution for injection
Human Or VET : Human
Route of Administration : intravitreal
Patent Expiration Date : 2018-04-03
Date Granted : 2008-06-10
Patent Expiration Date : 2016-03-28
Date Granted : 2011-10-18
Brand Name : LUCENTIS
Patent Number : 2213833
Filing Date : 1996-03-28
Strength per Unit : 10 mg / ml
Dosage Form : solution for injection
Human Or VET : Human
Route of Administration : intravitreal
Patent Expiration Date : 2016-03-28
Date Granted : 2011-10-18
Patent Expiration Date : 2016-03-28
Date Granted : 2011-10-18
Brand Name : LUCENTIS
Patent Number : 2213833
Filing Date : 1996-03-28
Strength per Unit : 10 mg / mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : INTRAVITREAL
Patent Expiration Date : 2016-03-28
Date Granted : 2011-10-18
Patent Expiration Date : 2018-04-03
Date Granted : 2008-06-10
Brand Name : LUCENTIS
Patent Number : 2286330
Filing Date : 1998-04-03
Strength per Unit : 10 mg / mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : INTRAVITREAL
Patent Expiration Date : 2018-04-03
Date Granted : 2008-06-10
